[Cited FineTest ELISA Kit] Current Research on Allergic Granulomatosis

FineTest ELISA kit contributes to the research on allergic granulomatosis. The immunoassay is designed to Epx level in culture supernatant.

Article Title: Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis
Journal Title: Nature Communications
DOI: 10.1038/s41467-025-68104-6
IF: 15.7
PMID: 41501017

Abstract:   Eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma (SEA) share a Type 2 (T2) inflammatory signature but exhibit distinct pathophysiology. We hypothesized that EGPA involves additional inflammatory mechanisms, beyond T2 immunity, that drive its systemic manifestations and treatment resistance. Using single-cell RNA sequencing, we identify interferon (IFN-I)-driven inflammation in EGPA, in contrast to TNF predominant pathway activation in SEA. IL1B+MX1+ neutrophils in EGPA express IFN-stimulated genes and promote tertiary lymphoid structure formation with autoantibody production. In addition, other IFN-activated granulocytes, including APOC1+ eosinophils, SCN7A+ mast cells, and basophils, further contribute to immune dysregulation in EGPA, unlike TNF activated granulocytes in SEA. Longitudinal single-cell analysis of EGPA reveals an IGF1+ macrophage population linked to EGPA relapse. In animal models of both conditions, IGF1 blockade attenuates T2 inflammation, mucin production, and goblet cell hyperplasia, highlighting IGF1 as a possible therapeutic target in T2 inflammation disease.

Keywords: Eosinophilic granulomatosis with polyangiitis (EGPA), Drug Therapy, Autoimmune Diseases, Inflammation, Systemic Vasculitis

Immunoassay

Validated Image

Figure Source: Nat Commun. 2026 Jan 7;17(1):1346. doi: 10.1038/s41467-025-68104-6.